SBIR/STTR Research Award

A Novel Human Primary Meibomian Gland Cell Platform for Dry Eye Therapeutics

Award identifier f75d05b89194772dc7271124dde689a8ac59585c857ce67acf4b9514dae28dc7Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$216,626

Program and phase

SBIR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Zen-Bio, Inc.
Proposal award date
2018-09-30
Contract end date
2019-08-31
UEI
LQS2WJFBBUQ3
Solicitation number
PAR16-375
Topic code
NIA

Research abstract

Dry eye diseaseDEDaffects visual function and quality of lifeand it is estimated to be prevalent inof adults agedyears old or older worldwide with females representing two thirds of this populationMeibomian glandMGdysfunction is age related and is the leading cause of DEDMuch of what is known about the agerelated changes in MGs has been derived from clinical studies performed in patients that measure functional and morphological changes in young and adult populations or on histopathological samplesbut the cellular and molecular mechanisms behind these changes are not completely understood due to the paucity of primary human tissues and glandsTo datethere is only one reported immortalized meibomian gland epithelial cellMGECline originating from a male donor used for DED researchindicating the need for additional cell lines to be generatedUtilizing our knowledge and previous experience isolating sebocyteswe successfully isolated and propagated MGECs from one donorThis proposal describes an approach to generate and characterize a bank of primary MGECs as well as immortalized cell lines from young and old male and female donors to provide commercially available resources to study MGECs originating from various demographicsUsing these newly generated linesthis proposal also outlines the establishment and validation of a high throughput screen to analyze compounds for their ability to modulate lipid levels in MGECs in search of compounds for a potential therapeutic treatment of DEDThe overall objective of this program is to provide commercially available primary and immortalized MGECs as well as to initiate the identification and characterization of a novel DED therapeutic that targets lipid production in meibomian glands Dry eye disease affectsof the worldwide populationyears old or older with an estimatedmillion people in the United States affected by this diseaseThere is an urgent need for better and more appropriate cell model systems to study the age related progression of this diseaseThis proposal focuses on the generation of primary and immortalized meibomian gland epithelial cells and their use in identifying novel drugs to treat dry eye disease

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

25 SBIR/STTR records share this UEI (2003–2019). Reported award amounts total $16,356,237. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.